Elicio Therapeutics reports Q3 EPS ($1.39), consensus (73c)

“We have made significant pipeline progress advancing our novel cancer immunotherapies, and we remain highly encouraged by the potential for our platform to provide a meaningful, broadly applicable, off-the-shelf therapeutic vaccine to treat common cancer types,” said Robert Connelly, Chief Executive Officer of Elicio. “During the third quarter and at the recent SITC conference, we presented data from our Phase 1a trial of ELI-002 in mKRAS-driven solid tumors, showing tumor biomarker reductions, robust T cell responses, antigen-spreading-and a potential DFS benefit. Our lead seven peptide ELI-002 program continues to be evaluated in a 135-patient randomized study in pancreatic ductal adenocarcinoma. Patient recruitment rates have exceeded initial expectations, reflecting high levels of investigator and patient interest. We continue to anticipate completion of enrollment in Q4 2024 and expect to conduct a pre-planned interim analysis, including DFS, in H1 2025. We are pleased to have strengthened our balance sheet, and such funding is expected to support operations into Q2 2025, beyond the anticipated AMPLIFY-7P interim analysis.”